Skip to main content
KPC PHARMACEUTICALS, INC. logo

KPC PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · 600422 ISIN · CNE0000015P8 LEI · 3003007ZALHXKUFMKN96 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 2,727 across all filing types
Latest filing 2020-06-05 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 600422

About KPC PHARMACEUTICALS, INC.

https://en.kpc.com.cn/

KPC Pharmaceuticals, Inc. specializes in the research, development, and manufacturing of pharmaceutical products, with a significant focus on natural and botanical medicines. The company is a global leader in the production of artemisinin-based anti-malarial treatments, including artemether and its derivatives. Its portfolio encompasses a wide range of therapeutic areas, notably cardiovascular and cerebrovascular health, where it utilizes Panax notoginseng saponins as a core component. KPC integrates traditional medicinal knowledge with modern pharmacological techniques to develop standardized botanical extracts and chemical drugs. The organization operates extensive production facilities and research centers dedicated to drug discovery and quality control. Its business activities extend to the distribution of healthcare products and the provision of medical services, aiming to provide comprehensive health solutions through innovation in natural medicine and biotechnology.

Recent filings

Filing Released Lang Actions
关于公开发行可转换公司债券摊薄即期回报对公司主要财务指标的影响与填补措施及相关主体承诺（二次修订稿）的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement by Kunming Pharmaceutical Corporation regarding its public issuance of convertible bonds, specifically addressing the dilution of immediate returns, measures to compensate for this dilution, and related commitments by the company and its controlling shareholders. It includes financial impact analysis, risk warnings, necessity and feasibility of the issuance, and detailed commitments from management and controlling shareholders. The content focuses on capital raising activities, financial metrics impact, and investor protection measures related to the convertible bond issuance. There is no indication that this is a full annual or interim financial report, audit report, or earnings release. It is not a simple announcement of a report publication but a substantive update on financing and capital structure changes. Therefore, the document fits best under the category of Capital/Financing Update (CAP). The document length (over 12,000 characters) and detailed financial analysis support this classification with high confidence.
2020-06-05 Chinese
德恒昆明关于昆药集团差异化分红的专项法律意见
Regulatory Filings Classification · 95% confidence The document is a legal opinion issued by a law firm regarding a company's differentiated dividend distribution plan. It discusses legal compliance, shareholder meetings, dividend amounts, and related corporate actions. It does not contain financial statements or detailed financial performance data itself, but rather a legal assessment of a specific corporate action (differentiated dividend). The document is not an annual report, earnings release, or financial supplement. It is not a proxy solicitation or voting result announcement. It is a specialized legal opinion related to dividend distribution, which fits best under Regulatory Filings (RNS) as it is a compliance/legal document that does not fit other categories.
2020-06-02 Chinese
2019年年度权益分派实施公告
Notice of Dividend Amount Classification · 95% confidence The document is an announcement regarding the implementation of the 2019 annual dividend distribution by Kunming Pharmaceutical Group Co., Ltd. It details the dividend per share, relevant dates for dividend registration, ex-dividend, and payment, as well as tax withholding information and the method of distribution. The document is relatively short (3007 characters) and focuses solely on dividend distribution details without containing full financial statements or comprehensive financial performance data. Therefore, it fits the category of a Notice of Dividend Amount (DIV) rather than an Annual Report or Earnings Release.
2020-06-02 Chinese
关于以集中竞价交易方式回购公司股份的进展公告
Transaction in Own Shares Classification · 100% confidence The document is a progress announcement regarding the company's share repurchase program. It details the number of shares repurchased, prices paid, and compliance with legal requirements. It does not contain financial statements or detailed financial analysis but reports on the status of the share buyback. This fits the description of a Transaction in Own Shares (POS) filing, which reports on the company's buyback activities.
2020-06-02 Chinese
关于使用部分闲置募集资金购买理财产品的进展公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from Kunming Pharmaceutical Group Co., Ltd. regarding the progress of using temporarily idle raised funds to purchase financial products. It includes specifics about the entrusted financial products, amounts, risk control, internal approvals, and impact on the company. The document references regulatory approvals from the China Securities Regulatory Commission and Shanghai Stock Exchange, details on fundraising amounts, and usage of funds. It is not a full financial report like an Annual Report (10-K) or Interim Report (IR), nor is it a brief announcement or a certification. The document is a regulatory announcement about the company's capital management activities, specifically the use of idle raised funds for financial management. This fits best under Capital/Financing Update (CAP) as it updates on the company's financing activities and capital usage. The document length (5892 characters) and content confirm it is a substantive update, not just a brief notice or report publication announcement.
2020-05-26 Chinese
关于控股股东股份解除质押的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the release of pledged shares by the controlling shareholder of the company. It details the number of shares released from pledge, the percentage of total shares, and confirms no further pledge plans. There is no financial data, no report attached or referenced as being published, and no mention of a meeting or voting results. This fits the category of a capital structure update related to share pledging status. Therefore, the document is best classified as a Capital/Financing Update (CAP). The document length is short and focused on share pledge status, not a full financial report or regulatory filing.
2020-05-26 Chinese

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.